107 related articles for article (PubMed ID: 2471652)
1. Bone marrow and blood involvement by non-Hodgkin's lymphoma: a study of clinicopathologic correlations and prognostic significance in relationship to the Working Formulation.
Morra E; Lazzarino M; Castello A; Inverardi D; Coci A; Pagnucco G; Orlandi E; Merante S; Magrini U; Zei G
Eur J Haematol; 1989 May; 42(5):445-53. PubMed ID: 2471652
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
Conlan MG; Bast M; Armitage JO; Weisenburger DD
J Clin Oncol; 1990 Jul; 8(7):1163-72. PubMed ID: 1694234
[TBL] [Abstract][Full Text] [Related]
3. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
[TBL] [Abstract][Full Text] [Related]
4. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group.
Meerwaldt JH; Carde P; Somers R; Thomas J; Kluin-Nelemans JC; Bron D; Noordijk EM; Cosset JM; Bijnens L; Teodorovic I; Hagenbeek A
Ann Oncol; 1997; 8 Suppl 1():67-70. PubMed ID: 9187434
[TBL] [Abstract][Full Text] [Related]
5. Non-Hodgkin's lymphoma in Saudi Arabia: prognostic factors and an analysis of the outcome of combination chemotherapy only, for both localized and advanced disease.
Ibrahim EM; Satti MB; Al-Idrissi HY; Al-Mulhim FA; Abssod GH; Abdel Jabar A
Eur J Cancer Clin Oncol; 1988 Mar; 24(3):391-401. PubMed ID: 2454821
[TBL] [Abstract][Full Text] [Related]
6. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
7. Non-Hodgkin's lymphomas in Turkey: eighteen years' experience at the Hacettepe University.
Barista I; Tekuzman G; Firat D; Baltali E; Kansu E; Kars A; Ozisik Y; Ruacan S; Uzunalimoğlu B; Karaağaoğlu E
Jpn J Cancer Res; 1994 Dec; 85(12):1200-7. PubMed ID: 7531679
[TBL] [Abstract][Full Text] [Related]
8. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen.
Bertini M; Freilone R; Vitolo U; Botto B; Ciotti R; Cinieri S; Di Nota A; Di Vito F; Levis A; Orsucci L; Pini M; Rota-Scalabrini D; Todeschini G; Resegotti L
Leuk Lymphoma; 1996 Aug; 22(5-6):483-93. PubMed ID: 8882962
[TBL] [Abstract][Full Text] [Related]
9. The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients.
Shpilberg O; Shiff J; Chetrit A; Ramot B; Ben-Bassat I
Cancer; 1994 Dec; 74(11):3029-33. PubMed ID: 7525042
[TBL] [Abstract][Full Text] [Related]
10. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
Schneider AM; Straus DJ; Schluger AE; Lowenthal DA; Koziner B; Lee BJ; Wong G; Clarkson BD
J Clin Oncol; 1990 Jan; 8(1):94-102. PubMed ID: 1688617
[TBL] [Abstract][Full Text] [Related]
11. Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma.
Joensuu H; Ristamäki R; Söderström KO; Jalkanen S
J Clin Oncol; 1994 Oct; 12(10):2167-75. PubMed ID: 7931487
[TBL] [Abstract][Full Text] [Related]
12. Non-Hodgkin's lymphomas in leukaemic phase: incidence, prognosis and therapeutic implications.
Tura S; Mazza P; Lauria F; Fiacchini M; Pileri S; Poletti G; Gherlinzoni F; Cantore M; Bandini G
Scand J Haematol; 1985 Aug; 35(2):123-31. PubMed ID: 3876594
[TBL] [Abstract][Full Text] [Related]
13. Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group.
Oguchi M; Ikeda H; Isobe K; Hirota S; Hasegawa M; Nakamura K; Sasai K; Hayabuchi N
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):161-8. PubMed ID: 10924986
[TBL] [Abstract][Full Text] [Related]
14. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
[TBL] [Abstract][Full Text] [Related]
15. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma.
Meyer RM; Quirt IC; Skillings JR; Cripps MC; Bramwell VH; Weinerman BH; Gospodarowicz MK; Burns BF; Sargeant AM; Shepherd LE
N Engl J Med; 1993 Dec; 329(24):1770-6. PubMed ID: 7694148
[TBL] [Abstract][Full Text] [Related]
16. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
17. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
18. High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma: the EBMT experience. Lymphoma Working Party of the European Group for Bone Marrow Transplantation.
Sweetenham JW; Proctor SJ; Blaise D; De Laurenzi A; Pearce R; Taghipour G; Goldstone AH; Laurenzi A [corrected to De Laurenzi A]
Ann Oncol; 1994; 5 Suppl 2():155-9. PubMed ID: 7515646
[TBL] [Abstract][Full Text] [Related]
19. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.
Waits TM; Greco FA; Greer JP; Johnson DH; Wolff SN; Stein RS; McMaster ML; Hainsworth JD
J Clin Oncol; 1993 May; 11(5):943-9. PubMed ID: 7683712
[TBL] [Abstract][Full Text] [Related]
20. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Santini G; Salvagno L; Leoni P; Chisesi T; De Souza C; Sertoli MR; Rubagotti A; Congiu AM; Centurioni R; Olivieri A; Tedeschi L; Vespignani M; Nati S; Soracco M; Porcellini A; Contu A; Guarnaccia C; Pescosta N; Majolino I; Spriano M; Vimercati R; Rossi E; Zambaldi G; Mangoni L; Rizzoli V
J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
